Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fortress Biotech Inc (FBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 179,642
  • Shares Outstanding, K 50,320
  • Annual Sales, $ 16,480 K
  • Annual Income, $ -55,100 K
  • 36-Month Beta 1.17
  • Price/Sales 10.02
  • Price/Cash Flow 0.00
  • Price/Book 1.93

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.13 +19.49%
on 04/24/17
4.02 -6.97%
on 03/28/17
+0.14 (+3.89%)
since 03/24/17
3-Month
2.29 +63.32%
on 01/30/17
4.14 -9.66%
on 03/17/17
+1.36 (+57.14%)
since 01/26/17
52-Week
1.88 +98.94%
on 12/19/16
4.14 -9.66%
on 03/17/17
-0.06 (-1.58%)
since 04/26/16

Most Recent Stories

More News
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer

Mustang Bio, Inc. ("Mustang"), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Manuel Litchman, M.D., has been appointed President and Chief Executive Officer. Dr. Litchman has also joined...

FBIO : 3.78 (+5.88%)
NHLD : 2.67 (+0.38%)
Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs

Checkpoint Therapeutics, Inc. ("Checkpoint") (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that preclinical data on its third-generation epidermal growth factor receptor ("EGFR")...

FBIO : 3.78 (+5.88%)
CKPT : 12.5000 (unch)
NHLD : 2.67 (+0.38%)
Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%

Fortress Biotech, Inc. (FBIO) moved big last session, as its shares rose over 8% on the day.

FBIO : 3.78 (+5.88%)
ANTH : 0.38 (unch)
Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

Checkpoint Therapeutics, Inc. ("Checkpoint") (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that preclinical data on its anti-PD-L1 antibody and EGFR inhibitor programs will be...

FBIO : 3.78 (+5.88%)
CKPT : 12.5000 (unch)
NHLD : 2.67 (+0.38%)
Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced financial...

FBIO : 3.78 (+5.88%)
NHLD : 2.67 (+0.38%)
Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders

Cyprium, NICHD establish CRADA to advance clinical development of Phase 3 candidate CUTX-101 (Copper Histidinate injection) in Menkes disease, a rare and fatal pediatric disease

FBIO : 3.78 (+5.88%)
NHLD : 2.67 (+0.38%)
Checkpoint Therapeutics to Present at the 29th Annual ROTH Conference

Checkpoint Therapeutics, Inc. ("Checkpoint") (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, III, President and CEO of Checkpoint, will present a company...

FBIO : 3.78 (+5.88%)
CKPT : 12.5000 (unch)
NHLD : 2.67 (+0.38%)
Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

Checkpoint Therapeutics, Inc. ("Checkpoint") (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent...

FBIO : 3.78 (+5.88%)
CKPT : 12.5000 (unch)
Fortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that...

FBIO : 3.78 (+5.88%)
NHLD : 2.67 (+0.38%)
National Holdings Corporation Announces Ex-Dividend Date for Warrant Dividend

National Holdings Corporation (NASDAQ:NHLD) ("National Holdings" or the "Company"), a full-service investment banking and asset management firm, announced yesterday that it had established January 18,...

FBIO : 3.78 (+5.88%)
NHLD : 2.67 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Support & Resistance

2nd Resistance Point 3.80
1st Resistance Point 3.68
Last Price 3.78
1st Support Level 3.37
2nd Support Level 3.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.